C31G oral rinseAlternative Names: 0.5% C31G oral rinse; 0.5% glyminox; Oramed
Latest Information Update: 07 Aug 2007
At a glance
- Originator Biosyn
- Mechanism of Action Cell membrane modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Candidiasis
Most Recent Events
- 31 Dec 2006 Discontinued - Phase-I/II for Candidiasis in USA (PO)
- 15 Dec 2004 Biosyn has been acquired by Cellegy Pharmaceuticals
- 12 Oct 2004 Cellegy Pharmaceuticals has entered into a definitive agreement to acquire Biosyn